KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Receivables (2016 - 2025)

Historic Receivables for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $8.1 billion.

  • Abbott Laboratories' Receivables rose 1541.63% to $8.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 billion, marking a year-over-year increase of 1541.63%. This contributed to the annual value of $6.9 billion for FY2024, which is 548.36% up from last year.
  • Per Abbott Laboratories' latest filing, its Receivables stood at $8.1 billion for Q3 2025, which was up 1541.63% from $8.0 billion recorded in Q2 2025.
  • In the past 5 years, Abbott Laboratories' Receivables ranged from a high of $8.1 billion in Q3 2025 and a low of $6.0 billion during Q1 2023
  • In the last 5 years, Abbott Laboratories' Receivables had a median value of $6.6 billion in 2023 and averaged $6.7 billion.
  • As far as peak fluctuations go, Abbott Laboratories' Receivables soared by 1893.0% in 2021, and later tumbled by 1614.43% in 2023.
  • Quarter analysis of 5 years shows Abbott Laboratories' Receivables stood at $6.5 billion in 2021, then dropped by 4.15% to $6.2 billion in 2022, then increased by 5.58% to $6.6 billion in 2023, then rose by 5.48% to $6.9 billion in 2024, then increased by 17.52% to $8.1 billion in 2025.
  • Its Receivables stands at $8.1 billion for Q3 2025, versus $8.0 billion for Q2 2025 and $7.3 billion for Q1 2025.